blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2026653

EP2026653 - ADMINISTRATION OF THE REG1 ANTICOAGULATION SYSTEM [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  22.04.2016
Database last updated on 05.10.2024
Most recent event   Tooltip22.04.2016Application deemed to be withdrawnpublished on 25.05.2016  [2016/21]
Applicant(s)For all designated states
Regado Biosciences, Inc.
318 Blackwell Street,Suite 130
Durham, NC 27701 / US
[2009/09]
Inventor(s)01 / RUSCONI, Christopher, P.
324 Blackwell Street, Suite 420
Durham, NC 27701 / US
02 / TONKENS, Ross, M.
120 Hamilton Hedge Place
Cary, NC 27519 / US
 [2009/09]
Representative(s)Hallybone, Huw George, et al
Carpmaels & Ransford LLP
One Southampton Row
London WC1B 5HA / GB
[N/P]
Former [2009/51]Hallybone, Huw George, et al
Carpmaels & Ransford 43-45 Bloomsbury Square
London WC1A 2RA / GB
Former [2009/09]Hallybone, Huw George, et al
Carpmaels & Ransford 43-45 Bloomsbury Square
London WC1A 2RA / GB
Application number, filing date07815043.025.05.2007
[2009/09]
WO2007US12625
Priority number, dateUS20060808987P26.05.2006         Original published format: US 808987 P
US20060847809P27.09.2006         Original published format: US 847809 P
US20060865352P10.11.2006         Original published format: US 865352 P
[2009/09]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2007140000
Date:06.12.2007
Language:EN
[2007/49]
Type: A2 Application without search report 
No.:EP2026653
Date:25.02.2009
Language:EN
The application published by WIPO in one of the EPO official languages on 06.12.2007 takes the place of the publication of the European patent application.
[2009/09]
Search report(s)International search report - published on:US28.02.2008
(Supplementary) European search report - dispatched on:EP17.10.2011
ClassificationIPC:A61K31/7088, A61P7/02
[2011/44]
CPC:
A61K49/00 (EP,US); A61K48/00 (KR); A61K31/00 (EP,US);
A61P39/02 (EP); A61P7/02 (EP)
Former IPC [2009/09]A01N43/04, A61K31/70, C12N15/00, A61K38/00, A61K31/715
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MT,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2009/09]
Extension statesALNot yet paid
BANot yet paid
HRNot yet paid
MKNot yet paid
RSNot yet paid
TitleGerman:VERWALTUNG EINES REG1-ANTIKOAGULIERUNGSSYSTEMS[2009/09]
English:ADMINISTRATION OF THE REG1 ANTICOAGULATION SYSTEM[2009/09]
French:ADMINISTRATION DU SYSTÈME D'ANTICOAGULATION REG1[2009/09]
Entry into regional phase23.12.2008National basic fee paid 
23.12.2008Search fee paid 
23.12.2008Designation fee(s) paid 
23.12.2008Examination fee paid 
Examination procedure23.12.2008Examination requested  [2009/09]
02.03.2009Amendment by applicant (claims and/or description)
01.12.2015Application deemed to be withdrawn, date of legal effect  [2016/21]
12.01.2016Despatch of communication that the application is deemed to be withdrawn, reason: renewal fee not paid in time  [2016/21]
Fees paidRenewal fee
23.12.2008Renewal fee patent year 03
26.05.2010Renewal fee patent year 04
27.05.2011Renewal fee patent year 05
30.03.2012Renewal fee patent year 06
10.05.2013Renewal fee patent year 07
16.05.2014Renewal fee patent year 08
Penalty fee
Additional fee for renewal fee
31.05.201509   M06   Not yet paid
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[XDY]WO2005106042  (REGADO BIOSCIENCES INC [US], et al) [XD] 7-19 * abstract * * p.55, In vivo activity of Apt39 and Apt7AD in cynomolgus Monkeys - p. 58 * [Y] 1-6;
 [YP]  - OMORI HISAKO ET AL, "Requiring lower warfarin dosages to achieve therapeutic anticoagulation is a strong risk factor for bleeding event", CIRCULATION, vol. 114, no. 18, Suppl. S, (20061031), 79TH ANNUAL SCIENTIFIC SESSION OF THE AMERICAN-HEART-ASSOCIATION; CHICAGO, IL, USA; NOVEMBER 12 -15, 2006, URL: http://circ.ahajournals.org/cgi/content/meeting_abstract/114/18_MeetingAbstracts/II_478-a, (20110926), XP002659967 [YP] 1-6 * abstract *
 [YP]  - CORDULA MEYER ZU SCHWABEDISSEN ET AL, "Obesity is associated with a slower response to initial phenprocoumon therapy whereas CYP2C9 genotypes are not", EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, SPRINGER, BERLIN, DE, (20060718), vol. 62, no. 9, doi:10.1007/S00228-006-0158-3, ISSN 1432-1041, pages 713 - 720, XP019421066 [YP] 1-6 * abstract * * p. 714, Independent variables * * p. 717, Obesity and phenprocoumon sensivity * * p. 719, col. 2, §1 *;; figure 1; table 5 *

DOI:   http://dx.doi.org/10.1007/s00228-006-0158-3
International search[X]US2003083294  (SULLENGER BRUCE A [US], et al);
 [XP]  - DYKE C.K. ET AL., "First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: a phase la pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity", CIRCULATION, (20061205), vol. 114, no. 23, pages 2490 - 2497, XP008102217

DOI:   http://dx.doi.org/10.1161/CIRCULATIONAHA.106.668434
 [A]  - DROLET D.W. ET AL., "Pharmacokinetics and safety of an anti-vascular endothelial growth factor aptamer (NX1838) following injection into the vitreous humaor of rhesus monkeys", MEDLINE, (200012), Database accession no. (11303960), XP008100856
    [ ] - PHARMA RES., vol. 17, no. 12, pages 1503 - 1510
 [Y]  - RUSCONI C.P. ET AL., "RNA aptamers as reversible antagonists of coagulation factor IXa", NATURE, (20020905), vol. 419, no. 6902, pages 90 - 94, XP002956811

DOI:   http://dx.doi.org/10.1038/nature00963
 [A]  - GOPINATH S.C. ET AL., "A potent anti-coagulant RNA aptamer inhibits blood coagulation by specifically blocking the extrinsic clotting pathway", THROMB HAEMOST., (200605), vol. 95, no. 5, pages 767 - 771, XP008103393

DOI:   http://dx.doi.org/10.1160/TH06-01-0047
 [X]  - RUSCONI C.P. ET AL., "Antidote-mediated control of an antocoagulant aptamer in vivo", NAT. BIOTECHNOL., (200411), vol. 22, no. 11, pages 1423 - 1428, XP008064496

DOI:   http://dx.doi.org/10.1038/nbt1023
 [A]  - BOOMER R.M. ET AL., "Conjugation to polyethylene glycol polymer promotes aptamer biodistribution to healthy and inflamed tissues.", MEDLINE, (2005), Database accession no. (16201906), XP008100857
    [ ] - OLIGONUCLEOTIDES, vol. 15, no. 3, pages 183 - 195
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.